Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q2 earnings results on Wednesday, August 5th, before market open.
The consensus EPS Estimate is $0.53 (-11.7% Y/Y) and the consensus Revenue Estimate is $3.94B (-9.2% Y/Y).
Analysts expect Non-GAAP gross margin of 51.5% and Non-GAAP operating margin of 23.8%.
Over the last 2 years, TEVA has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 14 downward. Revenue estimates have seen 2 upward revisions and 11 downward.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.